“Newgenco TangZhiShu Capsule” went through all strict formalities of safety evaluation and medical examination (including animal test and human clinical test) according to the standard procedures set out by Chinese regulatory agencies in 2002-2003 and was approved for manufacturing by SFDA of China in 2004. It was extracted from natural buckwheat seeds and contains a new kind of insulin sensitizer—D-chiro-inositol (DCI) & Myo-Inositol (MI) and demonstrated an excellent safety, efficacy profiles and dominant effect on patients with diabetes, hyperlipidemia, hypertension. “Newgenco TangZhiShu Capsule” was manufactured in a GMP standard by our two patented techniques. We discovered that natural buckwheat (Fagopyrum esculentum Moench, Fagopyrum trtarium Moench) seeds contains large amount of a new important mediator for insulin action in the derivation type. We have further developed a proprietary technology that easily and cost-effectively converts the derivatives to active mediator compounds and subsequently isolates the active compounds as a dietary supplement /pharmaceutical preparation, which we named “Newgenco TangZhiShu Capsule”. This technology was submitted out for patent application in in 2001, 2003 and granted in 2004, 2005. Quality Specification Total Chiro-Inositol ≥1700mg/ 100g (D-chiro-inositol and Myo-inositol) Total Flavones(Rutin as Standard) ≥460mg/ 100g Water ≤9% Ash ≤8.0% Lead ≤2.0mg/kg Arsenic ≤1.0 mg/kg Mercury ≤0.3mg/kg Physiological Functions • Reduces Serum Glucose in Streptozotocin-Diabetic Rats and in Type 2 diabetes patients have been tested • Dominant effect on hyperlipidemia rats have been tested. • Reported good effect on PCOS, hypertension, obesity(we plan to test it) Applications 1. Function food 2. Food additive 3. Pharmaceutical stuff Safety Superior safety profile with no side effect tested by animal experiments